We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

IPRU:AQUISEUImpresa SGPS SA Analysis

Data as of 2026-03-14 - not real-time

RON 1.33

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

The stock is trading at RON 1.325, just above the calculated support level of RON 1.295 and marginally below the 20‑day SMA (RON 1.326), indicating limited upside in the near term. Technical signals are mixed: the RSI sits at 50.07 (neutral), while the MACD histogram is negative and the MACD signal is labeled bearish, suggesting downward pressure. Volume is increasing, but the overall trend is classified as neutral and the 30‑day volatility is elevated at 21.7%, though the beta of 0.306 points to low systematic market risk.
Fundamentally, IPRU posted a 12.5% revenue growth year‑over‑year, with a gross margin of 32.9% and an operating margin of 12.7%, yet profitability remains modest (profit margin 6.7%). The company holds RON 27.44 M in cash against RON 20.48 M of debt, but a debt‑to‑equity ratio of 11.4 signals a heavy leverage burden, and free cash flow is negative (‑RON 11.56 M). The price‑to‑book ratio of 0.92 suggests the stock is undervalued relative to its book value, though the lack of earnings (PE 0) and zero dividend payout raise concerns about sustainability.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Price hovering just above support with limited upside
  • Bearish MACD signal indicating potential downside
  • High leverage increasing financial risk

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Revenue growth of 12.5% supporting earnings potential
  • Undervalued price‑to‑book ratio below 1.0
  • Negative free cash flow and high debt‑to‑equity ratio

Long Term

> 3 years
Positive
Model confidence: 6/10

Key Factors

  • Strong top‑line growth in a niche industrial segment
  • Valuation discount relative to book value
  • Potential for debt reduction and cash‑flow improvement over time

Key Metrics & Analysis

Financial Health

Revenue Growth12.50%
Profit Margin6.70%
ROE7.42%
ROA3.96%
Debt/Equity11.40
P/B Ratio0.9
Op. Cash FlowRON20.5M
Free Cash FlowRON-11557997
Industry P/E29.1

Technical Analysis

TrendNeutral
RSI50.1
SupportRON 1.29
ResistanceRON 1.37
MA 20RON 1.33
MA 50RON 1.34
MA 200RON 1.29
MACDBearish
VolumeIncreasing
Fear & Greed Index72.88

Valuation

GradeUndervalued
TypeBlend

Risk Assessment

Beta0.31
Volatility21.74%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.